Aclaris Therapeutics (ACRS) EBT Margin (2017 - 2026)
Aclaris Therapeutics (ACRS) recorded quarterly EBT Margin of 1035.97% in Q1 2026, up 36.42% quarter-over-quarter from 1629.34% in Q4 2025, and up 5805.0% on a YoY basis from 17.54% in Q1 2025.
Aclaris Therapeutics (ACRS) EBT Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' EBT Margin history runs 10 years deep, the most recent figure standing at 1035.97% for Q1 2026.
- In Q1 2026, EBT Margin rose 5805.0% year-over-year to 1035.97%; the TTM figure through Mar 2026 stood at 878.43% (down 13056.0% YoY), while the FY2025 annual figure was 878.33%, down 17285.0% from the prior year.
- EBT Margin was 1035.97% for Q1 2026 at Aclaris Therapeutics, up from 1629.34% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 10.57% in Q4 2023 to a low of 1702.25% in Q2 2023.
- Historically, EBT Margin has averaged 816.23% across 5 years, with a median of 922.34% in 2025.
- Biggest YoY gain for EBT Margin was 130507 bps in 2024; the steepest drop was 104872 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 375.07% in 2022, then soared by 97 bps to 10.57% in 2023, then slumped by 9917 bps to 1059.3% in 2024, then sank by 54 bps to 1629.34% in 2025, then soared by 36 bps to 1035.97% in 2026.
- The last three EBT Margin figures came in at 1035.97% (Q1 2026), 1629.34% (Q4 2025), and 464.69% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | -1,035.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,035.97% |
| Dec 31, 2025 | -1,629.34% |
| Sep 30, 2025 | -464.69% |
| Jun 30, 2025 | -922.34% |
| Mar 31, 2025 | -1,094.02% |
| Dec 31, 2024 | -1,059.30% |
| Sep 30, 2024 | -195.12% |
| Jun 30, 2024 | -397.18% |
| Mar 31, 2024 | -706.46% |
| Dec 31, 2023 | -10.57% |
| Sep 30, 2023 | -315.24% |
| Jun 30, 2023 | -1,702.25% |
| Mar 31, 2023 | -1,183.47% |
| Dec 31, 2022 | -375.07% |
| Sep 30, 2022 | -109.76% |
| Jun 30, 2022 | -1,373.95% |
| Mar 31, 2022 | -1,301.24% |
| Dec 31, 2021 | -1,525.18% |
| Sep 30, 2021 | -1,223.33% |
| Jun 30, 2021 | -987.17% |